Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $13.90.
MRVI has been the subject of a number of analyst reports. The Goldman Sachs Group reduced their price objective on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Thursday, November 9th. Royal Bank of Canada dropped their price target on shares of Maravai LifeSciences from $20.00 to $18.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 8th. Robert W. Baird lowered their price objective on shares of Maravai LifeSciences from $18.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 8th. KeyCorp lowered shares of Maravai LifeSciences from an “overweight” rating to a “sector weight” rating in a research report on Tuesday, August 8th. Finally, Morgan Stanley lowered their price target on shares of Maravai LifeSciences from $12.00 to $11.00 and set an “overweight” rating on the stock in a research report on Thursday, November 9th.
Hedge Funds Weigh In On Maravai LifeSciences
Maravai LifeSciences Stock Down 1.8 %
Shares of NASDAQ MRVI opened at $5.02 on Monday. The stock has a market capitalization of $1.26 billion, a P/E ratio of 27.89 and a beta of -0.11. The company has a 50-day moving average price of $7.91 and a 200-day moving average price of $10.71. Maravai LifeSciences has a 1 year low of $4.52 and a 1 year high of $16.90. The company has a debt-to-equity ratio of 0.62, a current ratio of 8.96 and a quick ratio of 8.33.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
- Five stocks we like better than Maravai LifeSciences
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- MarketBeat Week in Review – 11/13 – 11/17
- Canadian Penny Stocks: Can They Make You Rich?
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.